Martin David Harp

OCU410ST uses an adeno-associated virus delivery platform for the retinal delivery of the RORA gene.

The Investigational New Drug (IND) application from Complement Therapeutics for CTx001 was previously approved by the FDA in October 2025

The Part B dose-expansion portion is evaluating SB-007 for the treatment of Stargardt disease.

The JADE clinical study enrolled more than 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD).

According to the company, the FDA’s decision was supported by visual function results from the phase 2 ACUITY trial in ON.

The company did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held on January 6, 2026.

The company can now initiate its phase 1/2 CLARITY trial activities for its lead in vivo genome-editing program GEB-101 for TGFBI corneal dystrophy.

NCX 470 is Nicox’s lead dual-mechanism bimatoprost eye drop for lowering IOP in open-angle glaucoma or ocular hypertension.

Aldeyra met with the FDA on December 12, 2025, in which the FDA requested the company submit the CSR from the reproxalap dry eye disease field trial to the NDA.

The trial is being discontinued based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the trials for “futility."

While primary endpoint analysis showed no statistical difference in the rate of change in GA area between AVD-104 versus monthly avacincaptad pegol, 12-month results showed approximately 31% reduction in GA lesion growth rate versus growth rates in sham and natural history rates.

The company plans to submit its NDA package in the second half of 2026.

Alcon increases its acquisition offer for STAAR Surgical, emphasizing a final deal amid shareholder debates and delays in the merger process.

Xelafaslatide is a small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across multiple retinal diseases and conditions.

The study evaluated thermal dynamics associated with CW-TSCPC and TLT using MicroPulse technology, such as temperature peak, exposure duration, and thermal spread in a simulated ciliary body using computer modeling.

EndoArt is an artificial cornea endothelial layer made of a sterile biocompatible material, acrylic hydrophilic. According to the company it is the first synthetic implant to treat corneal edema.

The trial is evaluating the company’s femtosecond laser trabeculotomy procedure in comparison to selective laser trabeculoplasty

Formosa Pharmaceuticals partners with Rxilient Medical to commercialize APP13007, a new ophthalmic treatment for post-surgery inflammation and pain relief.

Earlier in 2025 it was announced that PainReform had acquired a majority equity interest in LayerBio, focusing on the company’s OcuRing-K technology.

Under the terms of the agreement Iolyx Therapeutics has granted Théa exclusive worldwide development and commercialization rights, excluding Asia, to ILYX-002 for the treatment of ocular surface diseases.

The SAPPHIRE trial evaluating the VisiPlate is currently underway across several sites across the US, with more site activations scheduled for 2026

K8 is a member of a new class of inflammasome-inhibiting drugs called kamuvudines.

Cyclosporine ophthalmic emulsion 0.05% is a topical immunomodulator to increase tear production in patients whose tear production is thought to be reduced due to ocular inflammation associated with dry eye syndrome.

The company noted that this approval marks Celltrion's first Health Canada–approved biologic product in ophthalmology.

This is the first submission for approval under the exclusive license and commercialization agreement for South Korea that was signed between LENZ and Lotus.

HUC1-394 is a peptide-based eye drop for dry eyes being developed by the company.

The DRAGON trial was a 24-month pivotal phase 3 trial evaluating Tinlarebant in adolescent STGD1 patients.

Kiora Pharmaceuticals advances ocular therapies with new patents for KIO-104, targeting retinal inflammation and enhancing treatment options.